Preoperative systemic inflammatory markers in different brain pathologies: an analysis of 140 patients

Kayhan, Ahmet; Korkmaz, Taha Şükrü; Baran, Oğuz; Kemerdere, Rahşan; Yenı, Seher Naz; Tanrıverdi, Taner

doi:10.5137/1019-5149.jtn.24244-18.2

Cited by 11 publications

(28 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has reported that the prognostic significance of PLR is far less than that of NLR. The level of PLR activation occurs prior to surgery in many intracranial neoplasms, PLR may not have the ability to differentiate glioma from meningioma or acoustic neuroma . Although relatively high levels of PLR were found in patients with glioma, the underlying mechanism for the elevation still needs further investigation.…”

Section: Discussionmentioning

confidence: 98%

“…In a clinical study with 166 patients with GBM, both NLR and PLR are independent prognostic factors for OS, and a low NLR contributes to a better prognosis. 9 Instead of NLR, Kayhan et al 10 suggested that PLR could be a diagnostic value in different metastasis from GBM. Preoperative RDW and PNI levels are also beneficial to evaluate glioma outcomes.…”

Section: Prognostic Role Of Inflammatory Markers In Gliomasmentioning

confidence: 99%

“…The level of PLR activation occurs prior to surgery in many intracranial neoplasms, PLR may not have the ability to differentiate glioma from meningioma or acoustic neuroma. 8,10 Although relatively high levels of PLR were found in patients with glioma, the underlying mechanism for the elevation still needs further investigation. For the LMR, there was no significant difference in the prognosis between The pooled hazard ratio (HR) of (a) neutrophil/lymphocyte ratio (NLR); (b) platelet/lymphocyte ratio (PLR); (c) prognostic nutritional index (PNI); (d) red cell distribution width (RDW); and (e) lymphocyte/monocyte ratio (LMR) for overall survival (OS) in patients with glioma.…”

Section: Complex Interactions Between Tumor Cells and Inflammatory Cymentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta‐Analysis

Wang¹,

Kang

Lin

et al. 2019

Clinical Translational Sci

View full text Add to dashboard Cite

Glioma is the most common malignant brain tumor and has high lethality. This tumor generated a robust inflammatory response that results in the deterioration of the disease. However, the prognostic role of systemic cellular inflammatory indicators in gliomas remains controversial. This meta‐analysis aimed to assess the prognostic significance of preoperative neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), red cell distribution width (RDW), and prognostic nutritional index (PNI) in patients with gliomas. Databases of PubMed, EMBASE, Web of Science, and The Cochrane Library were systematically searched for all studies published up to January 2019. Study screening and data extraction followed established Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. The Newcastle–Ottawa Scale was used to assess the quality of studies. Eighteen studies containing 3,261 patients were included. The analyses showed an increased NLR or RDW was found to be an independent predictor of worse survival in patients with gliomas (hazard ratio (HR): 1.38; 95% confidence interval (CI): 1.09–1.74; P = 0.008; and HR: 1.40; 95% CI: 1.13–1.74; P = 0.002, respectively). Furthermore, a higher PNI indicates a better overall survival (OS; HR: 0.57; 95% CI: 0.42–0.77; P = 0.0002). For the evaluation of PLR and LMR, none of these variables correlated with OS (P = 0.91 and P = 0.21, respectively). Our meta‐analysis indicates the NLR, RDW, and PNI rather than PLR and LMR are the independent index for predicting the OS of gliomas. Pre‐operative NLR, RDW, and PNI can help to evaluate disease progression, optimize treatment, and follow‐up in patients with gliomas.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Prognostic Role Of Inflammatory Markers In Gliomasmentioning

confidence: 99%

Section: Complex Interactions Between Tumor Cells and Inflammatory Cymentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta‐Analysis

Wang¹,

Kang

Lin

et al. 2019

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Some scholars thought the lymphocyte infiltration around brain tumors may mediate antitumor immune reaction and mean better prognosis, whereas the infiltration of neutrophils around tumors may result from the stimulation of neutrophil chemotactic factors and reactive oxygen species induced by tumor cells, and associates with a poor prognosis. 30,31 Lower lymphocyte counts and higher neutrophil counts suggest reduced lymphocytedependent antitumor immune response and increased neutrophil-dependent inflammatory reactions. 32 Due to the similar clinical symptoms and imaging characteristics, accurate differentiation between HGG and sBM is a common differential diagnosis problem in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

<p>Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis</p>

Liu¹,

Bu²,

Wu³

et al. 2020

CMAR

View full text Add to dashboard Cite

“…Furthermore, there is overwhelming evidence that platelet counts are not correlated with patient prognosis in glioma patients (62,70,71,93,(198)(199)(200)(201)(202)(203)(204)(205). Moreover, platelet counts are not different in glioma patients as compared to other intracranial pathologies such as epilepsy and non-glial brain tumors (54,206,207). Aside platelet counts, researchers, amongst us, have noted that platelets may have altered protein content (208) and RNA content, due to sequestration of tumorderived RNAs.…”

Section: Blood Plateletsmentioning

confidence: 99%

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

BackgroundGliomas are the most common and aggressive tumors of the central nervous system. A robust and widely used blood-based biomarker for glioma has not yet been identified. In recent years, a plethora of new research on blood-based biomarkers for glial tumors has been published. In this review, we question which molecules, including proteins, nucleic acids, circulating cells, and metabolomics, are most promising blood-based biomarkers for glioma diagnosis, prognosis, monitoring and other purposes, and align them to the seminal processes of cancer.MethodsThe Pubmed and Embase databases were systematically searched. Biomarkers were categorized in the identified biomolecules and biosources. Biomarker characteristics were assessed using the area under the curve (AUC), accuracy, sensitivity and/or specificity values and the degree of statistical significance among the assessed clinical groups was reported.Results7,919 references were identified: 3,596 in PubMed and 4,323 in Embase. Following screening of titles, abstracts and availability of full-text, 262 articles were included in the final systematic review. Panels of multiple biomarkers together consistently reached AUCs >0.8 and accuracies >80% for various purposes but especially for diagnostics. The accuracy of single biomarkers, consisting of only one measurement, was far more variable, but single microRNAs and proteins are generally more promising as compared to other biomarker types.ConclusionPanels of microRNAs and proteins are most promising biomarkers, while single biomarkers such as GFAP, IL-10 and individual miRNAs also hold promise. It is possible that panels are more accurate once these are involved in different, complementary cancer-related molecular pathways, because not all pathways may be dysregulated in cancer patients. As biomarkers seem to be increasingly dysregulated in patients with short survival, higher tumor grades and more pathological tumor types, it can be hypothesized that more pathways are dysregulated as the degree of malignancy of the glial tumor increases. Despite, none of the biomarkers found in the literature search seem to be currently ready for clinical implementation, and most of the studies report only preliminary application of the identified biomarkers. Hence, large-scale validation of currently identified and potential novel biomarkers to show clinical utility is warranted.

show abstract

Preoperative systemic inflammatory markers in different brain pathologies: an analysis of 140 patients

Cited by 11 publications

References 1 publication

Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta‐Analysis

Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta‐Analysis

<p>Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis</p>

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

Contact Info

Product

Resources

About